$SKIN
Beauty Health Co Stock $skin

$skin Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017236 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$117.5M	$86.28M	$75.42M
YoY Change	13.47%	14.4%	58.63%
Cost Of Revenue	$49.60M	$32.17M	$23.48M
YoY Change	55.58%	37.04%	48.58%
Gross Profit	$67.88M	$54.10M	$51.94M
YoY Change	-5.27%	4.17%	63.63%
Gross Profit Margin	57.78%	62.71%	68.87%
Selling, General & Admin	$78.14M	$69.08M	$62.67M
YoY Change	11.97%	10.23%	124.57%
% of Gross Profit	115.12%	127.68%	120.66%
Research & Development	$2.881M	$2.336M	$2.230M
YoY Change	10.77%	4.75%	53.58%
% of Gross Profit	4.24%	4.32%	4.29%
Depreciation & Amortization	$9.901M	$1.834M	$1.416M
YoY Change	115.71%	29.52%	105.22%
% of Gross Profit	14.59%	3.39%	2.73%
Operating Expenses	$81.02M	$71.41M	$64.90M
YoY Change	7.93%	10.04%	121.06%
Operating Profit	-$13.15M	-$17.31M	-$12.96M
YoY Change	285.17%	33.55%	-644.12%
Interest Expense	$2.685M	$3.417M	-$3.400M
YoY Change	-149.51%	-200.5%	-40.34%
% of Operating Profit
Other Income/Expense, Net	$11.63M	$418.0K	$48.08M
YoY Change	-30.94%	-99.13%	-906.49%
Pretax Income	$1.171M	-$25.95M	$35.12M
YoY Change	-85.38%	-173.88%	-1081.06%
Income Tax	-$2.193M	-$3.700M	$2.600M
% Of Pretax Income	-187.28%		7.4%
Net Earnings	$3.364M	-$22.29M	$32.51M
YoY Change	-57.58%	-168.55%	-1092.88%
Net Earnings / Revenue	2.86%	-25.83%	43.1%
Basic Earnings Per Share	$0.03	-$0.17	$0.22
Diluted Earnings Per Share	$0.03	-$0.17	-$0.13
COMMON SHARES
Basic Shares Outstanding	132.7M shares	132.5M shares	150.6M shares
Diluted Shares Outstanding	132.7M shares	132.4M shares	152.7M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$549.7M	$532.3M	$859.2M
YoY Change	-33.04%	-38.05%	31109.23%
Cash & Equivalents	$549.7M	$532.3M	$859.2M
Short-Term Investments
Other Short-Term Assets	$30.94M	$21.70M	$13.55M
YoY Change	52.14%	60.1%	2175.73%
Inventory	$107.0M	$122.1M	$47.03M
Prepaid Expenses
Receivables	$74.63M	$70.80M	$60.77M
Other Receivables	$5.642M	$1.600M	$1.801M
Total Short-Term Assets	$767.9M	$748.5M	$982.4M
YoY Change	-22.88%	-23.81%	29236.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.75M	$34.00M	$32.11M
YoY Change	-6.16%	5.89%
Goodwill	$125.4M	$125.2M	$123.8M
YoY Change		1.13%	25.61%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.86M	$15.63M	$8.026M
YoY Change	66.39%	94.74%
Total Long-Term Assets	$239.5M	$246.4M	$216.8M
YoY Change	9.27%	13.67%	-52.89%
TOTAL ASSETS
Total Short-Term Assets	$767.9M	$748.5M	$982.4M
Total Long-Term Assets	$239.5M	$246.4M	$216.8M
Total Assets	$1.007B	$995.0M	$1.199B
YoY Change	-17.08%	-17.03%	158.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.38M	$34.33M	$26.96M
YoY Change	-20.23%	27.33%
Accrued Expenses	$50.20M	$13.15M	$12.42M
YoY Change	5.2%	5.88%	1449.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$82.79M	$72.33M	$68.93M
YoY Change	-4.9%	4.93%	8373.57%
LONG-TERM LIABILITIES
Long-Term Debt	$736.3M	$735.2M	$731.0M
YoY Change	0.58%	0.58%
Other Long-Term Liabilities	$24.57M	$36.90M	$11.00K
YoY Change	-38.1%	335354.55%	-99.98%
Total Long-Term Liabilities	$760.8M	$772.1M	$11.00K
YoY Change	-1.41%	7018990.91%	-99.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$82.79M	$72.33M	$68.93M
Total Long-Term Liabilities	$760.8M	$772.1M	$11.00K
Total Liabilities	$845.6M	$847.3M	$857.5M
YoY Change	-1.97%	-1.19%	1153.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$395.6M	-$403.8M	-$386.2M
YoY Change		4.54%	467.81%
Common Stock	$14.00K	$14.00K	$16.00K
YoY Change		-12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$161.8M	$147.7M	$341.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.007B	$995.0M	$1.199B
YoY Change	-17.08%	-17.03%	158.7%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$3.364M	-$22.29M	$32.51M
YoY Change	-57.58%	-168.55%	-1092.88%
Depreciation, Depletion And Amortization	$9.901M	$1.834M	$1.416M
YoY Change	115.71%	29.52%	105.22%
Cash From Operating Activities	$21.97M	-$13.01M	-$38.47M
YoY Change	-170.1%	-66.18%	-3150.83%
INVESTING ACTIVITIES
Capital Expenditures	$3.219M	$2.319M	$3.149M
YoY Change	-194.57%	-26.36%	284.96%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$16.92M
YoY Change	-100.0%
Cash From Investing Activities	-$3.219M	-$21.68M	-$3.425M
YoY Change	-34.02%	533.11%	246.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.546M	-$2.195M	-$783.0K
YoY Change	-21.92%	180.33%	-117.89%
NET CHANGE
Cash From Operating Activities	21.97M	-$13.01M	-$38.47M
Cash From Investing Activities	-3.219M	-$21.68M	-$3.425M
Cash From Financing Activities	-1.546M	-$2.195M	-$783.0K
Net Change In Cash	17.20M	-$36.89M	-$42.68M
YoY Change	-145.04%	-13.57%	-1017.83%
FREE CASH FLOW
Cash From Operating Activities	$21.97M	-$13.01M	-$38.47M
Capital Expenditures	$3.219M	$2.319M	$3.149M
Free Cash Flow	$18.75M	-$15.33M	-$41.62M
YoY Change	-167.12%	-63.17%	-9495.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001818093
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39565
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	The Beauty Health Company
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1908962
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2165 Spring Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Long Beach
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90806
CY2023Q1	dei	City Area Code CityAreaCode	800
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	603-4996
CY2023Q1	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	SKIN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	132652184	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	532282000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568197000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3802000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2929000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	70795000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76494000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	122081000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1625000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1280000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21749000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26331000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	748532000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	781958000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18360000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18184000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15590000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15637000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	70835000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46386000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	125175000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	124593000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	831000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	815000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15630000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14193000	usd
CY2023Q1	us-gaap	Assets Assets	994953000	usd
CY2022Q4	us-gaap	Assets Assets	1001766000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	34330000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	30335000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18722000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21677000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13149000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15183000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4910000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4958000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1219000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	962000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	72330000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73115000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12267000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12689000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2941000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2011000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	24550000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	15473000	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	735201000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	734143000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	847289000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	837431000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132626954	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132626954	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132214695	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132214695	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	555046000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	550320000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3642000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4530000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-403754000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381469000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	147664000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	164335000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	994953000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1001766000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86278000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75415000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	32174000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	24530000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	54104000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	50885000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	38699000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	36407000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2336000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2230000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30379000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26261000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	71414000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	64898000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17310000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14013000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3417000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3400000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4315000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	-3000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	418000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-934000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9076000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-52052000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-877000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	368000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25947000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34070000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3662000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2615000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-22285000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	31455000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	888000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-145000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21397000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31310000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132420762	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150598105	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132420762	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152711698	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298034000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	31455000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7049000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-145000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	336393000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	164335000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-22285000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2195000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2034000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3577000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1310000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	888000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	147664000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-22285000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	31455000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1834000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1416000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1093000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	229000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3874000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3578000	usd
CY2023Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	548000	usd
CY2022Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	135000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1058000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1057000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	3337000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	668000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3577000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7049000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9076000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-52052000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1511000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1516000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4793000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14152000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15771000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11491000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	203000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1290000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3085000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6639000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2088000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2530000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13010000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38471000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2450000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	276000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2319000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3149000	usd
CY2023Q1	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	16915000	usd
CY2022Q1	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21684000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3425000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2195000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	783000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2195000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-783000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36889000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-42679000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	974000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568197000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	901886000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	532282000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	859237000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86278000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75415000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86278000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75415000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	40032000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38373000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	82049000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	71283000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	122081000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4000000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4154000	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2027000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1357000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4869000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5643000	usd
CY2023Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7826000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	10523000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18722000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21677000	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	5101000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4904000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3543000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2348000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2344000	usd
CY2023Q1	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	0	usd
CY2022Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	1819000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4505000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3768000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13149000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15183000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	14199000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	12494000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18360000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18184000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	143414000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	72579000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	70835000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	114806000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68420000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46386000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	124593000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	582000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	125175000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3700000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.141
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.077
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	900000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3577000000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7049000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	75100000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M7D
CY2021Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	11500000	shares
CY2021Q2	skin	The Registration Rights Agreement Filing Timeline TheRegistrationRightsAgreementFilingTimeline	P60D
CY2021Q2	skin	The Registration Rights Agreement Filing Timeline TheRegistrationRightsAgreementFilingTimeline	P60D
CY2021Q2	skin	The Registration Rights Agreement Number Of Demands For Registration Allowed TheRegistrationRightsAgreementNumberOfDemandsForRegistrationAllowed	2	demand
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	skin	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132626954	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132626954	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132214695	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132214695	shares
CY2022Q4	skin	Number Of Stock Repurchase Programs NumberOfStockRepurchasePrograms	2	program
CY2022Q3	skin	Number Of Stock Repurchase Programs NumberOfStockRepurchasePrograms	2	program
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22285000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	31455000	usd
CY2023Q1	skin	Warrant Down Round Feature Decrease In Net Income To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	0	usd
CY2022Q1	skin	Warrant Down Round Feature Decrease In Net Income To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	52052000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22285000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20597000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132420762	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150598105	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2113593	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132420762	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152711698	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298000000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26331000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	781958000	usd
CY2022Q4	us-gaap	Assets Assets	1001766000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381469000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	164335000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1001766000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	24530000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	50885000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14013000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34070000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	31455000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31310000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	31455000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11491000	usd

Files In Submission

Name	View Source	Status
skin-20230331_pre.xml	Edgar Link	unprocessable
skin-20230331_def.xml	Edgar Link	unprocessable
0001628280-23-017236-index-headers.html	Edgar Link	pending
0001628280-23-017236-index.html	Edgar Link	pending
0001628280-23-017236.txt	Edgar Link	pending
0001628280-23-017236-xbrl.zip	Edgar Link	pending
ex311-2023q110xq.htm	Edgar Link	pending
ex312-2023q110xq.htm	Edgar Link	pending
ex321-2023q110xq.htm	Edgar Link	pending
ex322-2023q110xq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skin-20230331.htm	Edgar Link	pending
skin-20230331.xsd	Edgar Link	pending
skin-20230331_cal.xml	Edgar Link	unprocessable
skin-20230331_lab.xml	Edgar Link	unprocessable
skin-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKIN
Beauty Health Co Stock $skin

2023 Q2 Form 10-Q Financial Statement

#000162828023017236 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN Beauty Health Co Stock $skin

2023 Q2 Form 10-Q Financial Statement

#000162828023017236 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN
Beauty Health Co Stock $skin